International Journal of Hepatology最新文献

{"title":"Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective.","authors":"Meseret Derbew Molla,&nbsp;Gashaw Dessie,&nbsp;Yonas Akalu,&nbsp;Birhanu Ayelign","doi":"10.1155/2020/2374615","DOIUrl":"https://doi.org/10.1155/2020/2374615","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is an aggressive primary hepatic malignancy with a significant morbidity and mortality rate. Although chemotherapy along with surgical incision is believed to be an effective therapeutic approach, to date recurrence is being lifted a major concern. Thus, identifying another best therapeutic approach is becoming the main aim of physicians and scholars. In support of this, recently, several studies reported a significant observation of Sirtuin1 (SIRT1) overexpression in the malignant tumor cells, including HCC. As a result, they believed that overexpression of SIRT1 may have an effect on the progression of HCC by targeting growth and/or apoptotic controlling transcriptional factors/signaling pathways. Similarly, other reports confirmed that SIRT1 inhibition had a direct or indirect role in the control of tumor cell growth and metastasis. Therefore, inhibiting the expression and activity of SIRT1 might have a therapeutic effect to handle HCC. However, there are a limited number of reviews regarding the issue, and here, we summarized hepatocellular expression of SIRT1 and its role on HCC progression.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"2374615"},"PeriodicalIF":1.8,"publicationDate":"2020-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/2374615","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38109789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines?","authors":"Baba Sulemana Mohammed, Matthew Aidoo","doi":"10.1155/2020/9750194","DOIUrl":"10.1155/2020/9750194","url":null,"abstract":"<p><p>The diverse influence of liver function on drug disposition can lead health-care practitioners to inappropriate drug selection, inappropriate drug dosing, or some level of therapeutic negativism. The aim of this study was to assess how drug prescribing in patients with liver cirrhosis at the Tamale Teaching Hospital comply with recommendations of pharmacotherapy and safety guidelines. A prospective cross-sectional study was conducted from February to July, 2019, at the medical ward of the Tamale Teaching Hospital. A total of 152 liver cirrhotic patients were included in this study. Common etiologies for liver cirrhosis were chronic hepatitis B 80 (52.6%) and chronic hepatitis C 30 (19.7%); about 12.5% of etiologies were unknown. Of the 1842 prescription issued, 69% (1270/1842) were compliant. Of the 572 noncompliant prescriptions, about 32% (183/572) were due to pharmacotherapy and 68% (389/572) due to safety guideline recommendations. There was a substantial number (31%) of prescription noncompliance with recommendations for pharmacotherapy and safety guidelines in liver cirrhotic patients at the tertiary hospital in northern Ghana. Prescribers need to be conscious of the role of the liver in drug elimination and prescribe as recommended by guidelines.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"9750194"},"PeriodicalIF":1.5,"publicationDate":"2020-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38059074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Knowledge of Hepatitis B Virus Infection among Pregnant Women in the Ningo-Prampram District, Ghana.","authors":"Precious Kwablah Kwadzokpui,&nbsp;Elliot Elikplim Akorsu,&nbsp;Albert Abaka-Yawson,&nbsp;Solomon Sosu Quarshie,&nbsp;Stephen Adomako Amankwah,&nbsp;Philip Apraku Tawiah","doi":"10.1155/2020/7965146","DOIUrl":"https://doi.org/10.1155/2020/7965146","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus (HBV) infection has been suggested to play a role in various adverse birth outcomes. The study determined the prevalence as well as knowledge of hepatitis B virus infection among pregnant women in the Ningo-Prampram District of the Greater Accra Region of Ghana.</p><p><strong>Materials and methods: </strong>A cross-sectional study using simple random sampling technique was used to recruit 213 pregnant women receiving antenatal care in three different health facilities (Prampram Polyclinic (PPC), Dangme Community Hospital (DCH), and Old Ningo Health Center (ONHC)) in the Ningo-Prampram District of Ghana from November 2018 to January 2019. A semi-structured questionnaire was used to collect data which included participants' HBsAg test results, sociodemographic and gynaecological characteristics, and their level of knowledge on HBV infection. Knowledge of the participants on HBV infection was classified as either excellent, good, or poor based on their cumulative percentage scores from the questionnaire according to Al Rubaish system of classification.</p><p><strong>Results: </strong>Overall low-intermediate prevalence of HBV infection was 3.3%; however, PPC recorded the highest prevalence of 4.0% while DCH and ONHC recorded 2.82% and 2.50%, respectively. Statistically significant association was observed between HBV infection and the health facility. Majority (77.40%) of the study participants had poor knowledge on HBV infection while only 14 (6.57%) had excellent knowledge on HBV. Regarding excellent knowledge, 8 (11.0%) among the participants were demonstrated by the majority of those who received antenatal care from DCH. Generally, knowledge on HBV and the infection was poor among the study participants. Knowledge on HBV infection was found to be associated with residential status (<i>p</i> = 0.006), educational level (<i>p</i> < 0.001), occupation (<i>p</i> < 0.001), and gestational period (<i>p</i> < 0.001). Participant's knowledge was also significantly associated with the health facility (<i>p</i> = 0.027).</p><p><strong>Conclusion: </strong>HBV infection among pregnant women is prevalent in the Ningo-Prampram District even though the prevalence is not very high. The majority of pregnant women in the Ningo-Prampram District inadequate knowledge on HBV infection and it mode of transmission. Intensive public health education on the HBV infection is required in the district to help prevent and manage future transmissions as well as inform the population about the negative side effects of the virus and the need to prevent it by way of vaccination.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"7965146"},"PeriodicalIF":1.8,"publicationDate":"2020-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/7965146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37937981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isoniazid and Rifampicin Produce Hepatic Fibrosis through an Oxidative Stress-Dependent Mechanism.","authors":"Ayan Biswas,&nbsp;Suman Santra,&nbsp;Debasree Bishnu,&nbsp;Gopal Krishna Dhali,&nbsp;Abhijit Chowdhury,&nbsp;Amal Santra","doi":"10.1155/2020/6987295","DOIUrl":"https://doi.org/10.1155/2020/6987295","url":null,"abstract":"<p><strong>Methods: </strong>A combined dose of INH (50 mg) and RMP (100 mg) per kg body weight per day was administered to mice by oral gavage, 6 days a week, for 4 to 24 weeks for the assessment of liver injury, oxidative stress, and development of hepatic fibrosis, including demonstration of changes in key fibrogenesis linked pathways and mediators.</p><p><strong>Results: </strong>Progressive increase in markers of hepatic stellate cell (HSC) activation associated with changes in matrix turnover was observed between 12 and 24 weeks of INH-RMP treatment along with the elevation of liver collagen content and significant periportal fibrosis. These were associated with concurrent apoptosis of the hepatocytes, increase in hepatic cytochrome P450 2E1 (CYP2E1), NADPH oxidase (NOX) activity, and development of hepatic oxidative stress.</p><p><strong>Conclusions: </strong>INH-RMP can activate HSC through generation of NOX-mediated oxidative stress, leading to the development of liver fibrosis.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"6987295"},"PeriodicalIF":1.8,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6987295","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37904618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Many Difficulties and Subtleties in the Cognitive Assessment of Chronic Hepatitis C Infection.","authors":"Jefferson Abrantes,&nbsp;Daniel Simplicio Torres,&nbsp;Carlos Eduardo Brandão-Mello","doi":"10.1155/2020/9675235","DOIUrl":"https://doi.org/10.1155/2020/9675235","url":null,"abstract":"<p><p>Since the discovery of HCV in 1989, several diseases have been related to chronic infection by this virus. Often, patients with hepatitis C virus (HCV) complain of cognitive impairment even before the development of hepatic cirrhosis, which they described as \"brain fog.\" Several studies have proposed a link between chronic HCV infection and the development of cognitive alterations, but the inclusion of confounding factors in their samples significantly limits the analysis of the results. In this article, we will give an overview about cognitive dysfunction in patients with HCV.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"9675235"},"PeriodicalIF":1.8,"publicationDate":"2020-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9675235","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease.","authors":"Alireza Meighani,&nbsp;Maryam Alimirah,&nbsp;Mayur Ramesh,&nbsp;Reena Salgia","doi":"10.1155/2020/1874570","DOIUrl":"https://doi.org/10.1155/2020/1874570","url":null,"abstract":"<p><strong>Background: </strong>Fecal microbiota transplantation (FMT) is a well-established therapeutic option for patients with antibiotic resistant <i>Clostridioides difficile</i> infection (CDI). However, the efficacy of FMT in patients with chronic liver disease remains elusive.</p><p><strong>Aims: </strong>We studied the effect of FMT on chronic liver disease (CLD) patients with CDI at our tertiary medical center.</p><p><strong>Methods: </strong>A cohort of all patients who received FMT from December 2012 to May 2014 for refractory or recurrent CDI was identified. Patients were monitored for a year after FMT. Descriptive analysis was conducted to compare the effect of FMT in patients with and without CLD.</p><p><strong>Results: </strong>A total of 201 patients with CDI received FMT, 14 of which had a history of CLD. Nine of these patients exhibited cirrhosis of the liver with a mean Child-Turcotte-Pugh score of 8. CDI development in these patients was associated with recent exposure to antibiotics and was observed to be significantly different between both groups (17% of CLD patients vs. 58% in the general cohort, <i>p</i> = 0.01). Four patients with CLD received >1 FMT, of which 2 did not respond to treatment. There was no significant difference between patients with liver disease and the rest of the cohort with regard to FMT response (12/14 (87%) vs. 164/187 (88%), <i>p</i> = 0.01). Four patients with CLD received >1 FMT, of which 2 did not respond to treatment. There was no significant difference between patients with liver disease and the rest of the cohort with regard to FMT response (12/14 (87%) vs. 164/187 (88%).</p><p><strong>Conclusion: </strong>FMT is a safe and effective therapy against CDI for patients with CLD and cirrhosis.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"1874570"},"PeriodicalIF":1.8,"publicationDate":"2020-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/1874570","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37634072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.","authors":"Fred Poordad,&nbsp;Norah A Terrault,&nbsp;Naim Alkhouri,&nbsp;Wei Tian,&nbsp;Lee F Allen,&nbsp;Mordechai Rabinovitz","doi":"10.1155/2020/5421632","DOIUrl":"https://doi.org/10.1155/2020/5421632","url":null,"abstract":"<p><strong>Aims: </strong>Thrombocytopenia complicates the management of patients with chronic liver disease (CLD) undergoing invasive procedures with a bleeding risk. Until recently, prophylactic platelet transfusion was the only treatment option, but has significant safety and efficacy limitations. Phase 3 data demonstrated the superiority of avatrombopag to placebo in reducing platelet transfusions for bleeding, supporting its recent approval.</p><p><strong>Methods: </strong>Integrated analyses of pooled data (<i>N</i> = 435) from two randomized, double-blind, placebo-controlled, phase 3 studies assessed the original efficacy endpoints. Additional analyses included subgroup analyses, alternate Baseline platelet count definitions, and another efficacy endpoint.</p><p><strong>Results: </strong>Avatrombopag was superior to placebo in increasing patients not requiring a platelet transfusion or rescue procedure, those achieving a platelet count ≥50 × 10⁹/L on Procedure Day, and the change in platelet counts from Baseline. The avatrombopag treatment effect was consistently positive across clinically important disease and Baseline clinical characteristic subgroups, and using alternate Baseline platelet count cohort definitions. Similarly, more avatrombopag-treated patients achieved ≥50 × 10⁹/L platelets with an increase of ≥20 × 10⁹/L from Baseline. The incidence and severity of adverse events were similar between avatrombopag and placebo. Further, safety data demonstrated a low risk for thromboembolic events and hepatotoxicity.</p><p><strong>Conclusion: </strong>These integrated analyses confirmed the superiority of avatrombopag to placebo in reducing platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD scheduled to undergo an invasive procedure, and its tolerable safety profile. Importantly, these data warrant reconsideration of clinical decision making regarding the need to treat thrombocytopenia in patients with CLD. This trial was registered with NCT01972529 and NCT01976104.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"5421632"},"PeriodicalIF":1.8,"publicationDate":"2020-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/5421632","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37634073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Study of Protective Effect of Cimetidine and Verapamil on Paracetamol-Induced Hepatotoxicity in Mice.","authors":"Lubna Danish,&nbsp;Riffat Siddiq,&nbsp;Sarwat Jahan,&nbsp;Mehwish Taneez,&nbsp;Manzoor Khan,&nbsp;Marva Sandhu","doi":"10.1155/2020/9185361","DOIUrl":"https://doi.org/10.1155/2020/9185361","url":null,"abstract":"<p><p>Paracetamol, chemically known as acetaminophen, if taken in higher doses has hepatotoxic potential. Cimetidine by inhibiting the cytochromal enzymes and reducing the production of the toxic metabolite can reduce the hepatotoxic potential while Verapamil can act as a hepatoprotective by maintaining calcium homeostasis. The present study was conducted to study the hepatoprotective activity of Cimetidine and Verapamil against the toxicity induced by paracetamol. In addition to the group receiving only distilled water or 300 mg/kg paracetamol additional groups were added treated with 150 mg/kg Cimetidine and Verapamil alone or both. The Liver function tests and histopathology revealed hepatotoxicity in the group receiving paracetamol (PCM) while normal parameters were observed in the groups receiving Cimetidine and Verapamil. Our results strongly suggested that Cimetidine and Verapamil possess hepatoprotective potential against paracetamol induced hepatotoxicity.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"9185361"},"PeriodicalIF":1.8,"publicationDate":"2020-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9185361","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37677199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, Attitude, and Practice towards Hepatitis B Virus among Pregnant Women Attending Antenatal Care at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.","authors":"Teklay Gebrecherkos,&nbsp;Getu Girmay,&nbsp;Mulualem Lemma,&nbsp;Markos Negash","doi":"10.1155/2020/5617603","DOIUrl":"https://doi.org/10.1155/2020/5617603","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus (HBV) infection remains a serious public health concern worldwide. Mother-to-child transmission (MTCT) is the major mode in endemic areas, including Ethiopia, where little is known about pregnant women's knowledge, attitudes, and practice towards HBV infection and MTCT. Therefore, the study is aimed at determining the knowledge, attitude, and practice towards HBV among pregnant women attending antenatal care.</p><p><strong>Method: </strong>A cross-sectional study was conducted from February to April 2018, at the University of Gondar Comprehensive Specialized Hospital. A total of 354 pregnant women were selected by systematic random sampling and included in this study. KAP of participants on HBV MTCT was assessed using a structured questionnaire. Data was analyzed using SPSS version 22 software.</p><p><strong>Result: </strong>The total response rate was 100% (354/354). Out of the 354 participants, 73.4% were within the poor knowledge. Only 18.9% of the respondents know HBV can be transmitted from mother to child during pregnancy. Less than half (43.8) of the participants think that they will never be infected with HBV, and 47.7% of them go to traditional healers when they have symptoms of HBV. Majority of the respondents (85.87%) had never screened for HBV, and only 28.5% of the participants believed that hepatitis B can cause liver cancer. In multivariable analysis, residence, income, and educational level were associated with mean score knowledge and attitude.</p><p><strong>Conclusions: </strong>Knowledge about HBV among pregnant women was found to be poor, and their attitude and practice were also limited. Therefore, extensive health education program should be given to the pregnant women to increase their awareness towards HBV infection. All pregnant women should be screened for HBV as part of ANC follow-up.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"5617603"},"PeriodicalIF":1.8,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/5617603","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37608334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus.","authors":"Pradeep Kumar Mada,&nbsp;Matthew E Malus,&nbsp;Arvin Parvathaneni,&nbsp;Bing Chen,&nbsp;Gabriel Castano,&nbsp;Sharon Adley,&nbsp;Maureen Moore,&nbsp;Michinari Hieda,&nbsp;Mohammed J Alam,&nbsp;Mark Feldman,&nbsp;John William King","doi":"10.1155/2020/6438753","DOIUrl":"https://doi.org/10.1155/2020/6438753","url":null,"abstract":"<p><strong>Aim: </strong>To assess the effect of treating chronic hepatitis C virus (HCV) infection with direct acting antiviral drugs (DAAs) on glycemic control in patients with concomitant diabetes mellitus (DM).</p><p><strong>Methods: </strong>We performed a retrospective case-control study in a viral hepatitis ambulatory clinic in Shreveport, Louisiana, during the period 11/01/2014 to 12/31/2017. All the clinic patient ages 18 years and above with treatment-naïve/biopsy-proven chronic hepatitis C and DM (hemoglobin A1C level ≥ 6.5%) who were eligible for treatment were included in the study. Of 118 such patients, 59 were treated with oral DAAs for 8-12 weeks with the goal of achieving a sustained virologic response (SVR). A control group of 59 patients did not receive treatment for their hepatitis C and was followed in the clinic. Patients in the control group did not receive treatment either due to insurance issues or refusal of hepatitis C treatment.</p><p><strong>Results: </strong>Fifty-five of the 59 patients treated with DAAs (93%) achieved a SVR. Six months after treatment completion, their mean ± SEM HbA1C level had decreased by 1.1 ± 0.03% (<i>P</i> < 0.0001). Four of the 59 patients treated with DAAs did not achieve a SVR. Their mean HbA1C 6 months after treatment completion had increased by 0.8 ± 0.2%. Furthermore, there was no improvement in HbA1C levels over time in the untreated group (mean HbA1C increase, 0.2 ± 0.05%; <i>P</i> < 0.0001 vs. the treatment group, which had a mean HbA1C decrease of 0.9 ± 0.2%).</p><p><strong>Conclusion: </strong>This controlled study demonstrated that treatment of chronic hepatitis C with DAAs results in statistically significant and meaningful reductions in hemoglobin A1C levels in patients with coexisting diabetic mellitus if a SVR is achieved.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"6438753"},"PeriodicalIF":1.8,"publicationDate":"2020-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6438753","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37923349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}